Belvedere Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Belvedere Trading’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-400	Closed	-$1.51K	–	995
2023 Q3	$1.51K	Buy	+400	New	+$2.63K	﹤0.01%	593

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CST

Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Belvedere Trading's SPRY Position: Q4 2023 in Review

Belvedere Trading sold out of ARS Pharmaceuticals (SPRY) in Q4 2023, closing a stake of 6,143 shares — an estimated $23.2K sold.

Belvedere Trading first reported a position in SPRY in Q2 2022 and held it in 2 quarters. The position peaked at $277K in Q2 2022. 100 funds tracked by Wall St. Rank hold SPRY as of Q4 2023.

Belvedere Trading reported no remaining ARS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 6,143 ARS Pharmaceuticals shares in Q4 2023, an estimated $23.2K.
Belvedere Trading first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Belvedere Trading's ARS Pharmaceuticals position peaked at $277K in Q2 2022.
100 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.